Press Release
February 2, 2018

resTORbio Closes $97.8 Million Initial Public Offering

The Life Sciences team advised resTORbio on the closing of its initial public offering of 6,516,667 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 850,000 additional shares. The gross proceeds from the offering are approximately $97.8 million, before deducting underwriting discounts and commissions and estimated offering expenses.

resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.

The Goodwin team was led by partners Mitchell Bloom and Danielle Lauzon and included associates James Xu and Gabriela Morales-Rivera.